Exiqon Q2 Revenues Shrink 8 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon reported today an 8 percent decrease year over year in its second quarter revenues.

For the three months ended June 30, revenues totaled DKK 30.7 million ($5.5 million), down from DKK 33.3 million in the year-ago period. The firm said research product sales and services declined 3 percent year over year to DKK 24.9 million in the quarter, while service revenues fell 10 percent to DKK 3.7 million.

Exiqon did not break out the rest of its revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.